Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research
Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospitals and industry, has just announced the receipt of a critical ninth US Patent, entitled “Conjugated Polyelectrolytes and Methods of Using the Same.” U.S. Patent No. 9,750,250 issued September 5, 2017. Canadian Patent No. 2,973,982 allowed August 14, 2017. European/Asian Patent Numbers to follow.
The Patent grants Biosafe Defenses a method of disinfecting an object using light-activated conjugated polyelectrolytes (CPEs), which thereby can inactivate and destroy molds, viruses, fungal yeast, and antibiotic-resistant bacteria. To perform this task, the Patent grants exclusivity to Biosafe Defenses to provide an antimicrobial substrate such as a wipe, tissue, bandage, medical device, surgical instrument, or even a textile that, when treated with Biosafe’s proprietary CPEs, delivers long-term protection against some of the world’s deadliest pathogens, long after bleaches have already lost their killing ability.
The technology envisions germ-killing clothing, or metals like surgical instruments or plastics such as the pull-down table of an airplane food tray, being coated with the technology, and thereafter enabling that object to kill bacteria or viruses on contact due to of the product’s light-activation technology. Diapers, sponges, countertops or food preparation surfaces could enjoy the same benefits. The hospital industry could especially benefit, as hospital-associated infections (HAIs) continue to be a growing concern for doctors, patients, and the cleaning staff who frequently fight to ward off multidrug-resistant strains that are often fatal.
“A better solution than bleaches or current disinfectants is needed, which Biosafe’s unique compounds can deliver,” said Biosafe CEO Dr. Harry Pappas. “This is a very important Patent for our company. The antimicrobials encompassed by this Patent are perhaps the most promising compounds in our library in that they are safe to use, yet still able to confer protection against even the most robust microbes. Several studies suggest that these compounds will perform very well in our anticipated EPA trials to come.”
ABOUT BIOSAFE DEFENSES LLC: Currently, the Company is in the process of developing a wipe which will deliver powerful disinfectant properties to everything that the wipe comes in contact with, from bed rails to door knobs and other germ carrying high contact surfaces. The company originated from technology jointly developed by The University of New Mexico and University of Florida funded by millions of dollars of Government research contracts over a ten-year span from the US Defense Threat Reduction Agency (DTRA). The company has recently emerged from “stealth mode” and is seeking global industry partners for various applications of its technology.
Biosafe Defenses LLC
Harry Pappas Ph.D., CEO
1-508-259-7796 / 1-800-488-2001
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia12.12.2017 00:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery). The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005311/en/ ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central
NTT Communications Strengthens its DDoS Protection Services with New Detection Solution11.12.2017 23:00 | Pressemelding
NTT Communications Corporation (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), announced that it is expanding its Distributed Denial of Service Protection Services (DPS) with the addition of DPS Detect. This new solution can help customers detect potential attacks directed to their networks and initiate mitigations faster. DDoS attacks can strike at any time, potentially crippling network infrastructure and severely degrading the performance and reachability of a website or other IP-accessible assets. The expanded DPS suite of services will enable Global IP Network customers around the world to easily customize the level of service and assistance that best fits their needs. “Network security is one of the top priorities for our company,” said Michael Wheeler, executive vice president of the NTT Communications
Interactive Brokers Launches Bitcoin Futures Trading at the Start of Trading December 10th, 201711.12.2017 16:28 | Pressemelding
Interactive Brokers Group, Inc. (NASDAQ GS:IBKR), a global electronic brokerage firm, began offering clients the ability to trade bitcoin futures at the start of trading on the Cboe Futures Exchange (CFE) on Sunday night, December 10th, 2017. In addition to offering bitcoin futures from the CFE, under the ticker symbol GXBT, the company plans to offer bitcoin futures from the Chicago Mercantile Exchange (CME) at the scheduled start of trading December 18th using the symbol BRR. IBKR was there at the start of trading and its systems operated normally. “Interactive Brokers was on the buy side of the low print of 14,710,” said Thomas Peterffy, founder, Chairman and CEO of Interactive Brokers. “A Registered Investment Advisor on the Interactive Brokers platform purchased two March contracts in the first minute of trading.” As of 9:15am ET on Monday, the company said that
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00 | Pressemelding
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice
Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47 | Pressemelding
The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18 | Pressemelding
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom